Scalper1 News
British drug giant AstraZeneca (AZN) issued a mixed Q4 report and guidance Thursday morning, knocking down the stock, though some on Wall Street took notice of the fact that it’s advancing its Alzheimer’s disease candidate to phase-three testing. The company said Q4 revenue dropped 6% from the year-earlier quarter to $6.84 billion, missing analysts’ consensus of $6.91 billion. Core EPS of $1.23 a share beat estimates by a penny, but was down 21% Scalper1 News
Scalper1 News